Effects of thrombin, PAR-1 activating peptide and a PAR-1 antagonist on umbilical artery resistance in vitro

Reproductive Biology and Endocrinology

Volumn 3, Issue , 2005, Pages

  O'Loughlin, Aonghus J ^a   O'Sullivan, Crochan J ^a   Ravikumar, Nandini ^a   Friel, Anne M ^a   Elliott, John T ^b   Morrison, John J ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b NATIONAL INSTITUTE OF STANDARDS AND TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE ACTIVATED RECEPTOR 1; RECEPTOR BLOCKING AGENT; THROMBIN;

ADULT; ARTERY RESISTANCE; ARTICLE; BLOOD VESSEL TONE; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; FETOPLACENTAL UNIT; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; IN VITRO STUDY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; UMBILICAL ARTERY; VASODILATATION;

EID: 18144385506     PISSN: 14777827     EISSN: 14777827     Source Type: Journal    
DOI: 10.1186/1477-7827-3-8     Document Type: Article

References (24)

1. Rayne SC, Kraus FT: Placental thrombin and other vascular lesions. Classification, morphology, and clinical correlations. Pathol Res Pract 1993, 189:2-17.
2. Salafia CM, Minior VK, Pezullo JC, Popek EJ, Rosenkrantz TS, Vintzileos AM: Intrauterine growth restriction in infants of less than thirty-two weeks gestation: associated placental pathological features. Am J Obstet Gynecol 1995, 173:1049-1057.
3. Mitra SC, Seshan SV, Riachi LE: Placental vessel morphometry in growth retardation and increased resistance of the umbilical artery Doppler flow. J Matern Fetal Med 1998, 7: 277-286.
4. Chaiworapongsa T, Yoshimatsu J, Espinoza J, Kim YM, Berman S, Edwin S, Yoon BH, Romero R: Evidence if in vivo generation of thrombin in patients with small-for-gestational-age fetuses and pre-eclampsia. J Matern Fetal Neonatal Med 2002, 11:362-367.
5. Macfarlane SR, Seatter MJ, Kanke T, Hunter GD: Plevin Proteinase-activated receptors. Pharmacol Rev 2001, 53: 245-282.
6. Vergnolle N, Wallace JL, Bunnett NW, Hollenberg MD: Protease-activated receptors in inflammation, neuronal signalling and pain. Trends Pharmacol Sci 2001, 22:146-152.
7. Hollenberg MD: Protease-mediated signalling: new paradigms for cell regulation and drug development. Trends Pharmacol Sci 1996, 17:3-6.
8. Cocks TM, Moffatt JD: Protease-activated receptors: sentries for inflammation? Trends Pharmacol Sci 2000, 21: 103-108.
9. Cicala C, Bucci M, De Dominicis G, Harriot P, Sorrentino L, Cirino G: Bronchoconstrictor effect of thrombin and thrombin receptor activating peptide in guinea-pigs in vivo. Br J Pharmacol 1999, 126:478-484.
10. Vergnolle N: Review article: protease-activated receptors - novel signals for gastrointestinal pathophysiology. Aliment Pharmacol Ther 2000, 14:257-266.
11. Coughlin SR: How the protease thrombin talks to cells. Proc Natl Acad Sci USA 1999, 96:11023-11027.
12. Coughlin SR: Thrombin signalling and protease-activated receptors. Nature 2000, 407:258-264.
13. O'Sullivan CJ, Allen NM, O'Loughlin AJ, Friel AM, Morrison JJ: Thrombin and PAR-1 Activating peptide: Effects on human uterine contractility in vitro. Am J Obstet Gynecol 2004, 190: 1098-1105.
14. Patterson C, Stouffer GA, Madamanchi N, Runge MS: New tricks for old dogs: Non-thrombotic effects of thrombin in vessel wall biology. Circ Res 2001, 88:987-1008.
15. Hamilton JR, Moffatt JD, Frauman AG, Cocks TM: Protease-activated receptor (PAR) 1 but not PAR2 or PAR4 mediates endothelium-dependent relaxation to thrombin and trypsin in human pulmonary arteries. J Cardiovasc Pharmacol 2001, 38: 108-119.
16. Dennedy MC, Houlihan DD, McMillan HM, Morrison JJ, β2 and β3-adrenoceptor agonists: Human myometrial selectivity and effects on umbilical artery tone. Am J Obstet Gynecol 2002, 187: 641-647.
17. Potter SM, Dennedy MC, Morrison JJ: Corticosteroids and fetal vasculature: Effects of hydrocortisone, dexamethasone and betamethasone on human umbilical artery. BJOG 2002, 109: 1126-1131.
18. Elliott JT, Hoekstra WJ, Maryanoff BE, Prestwich GD: Photoactivatable peptides based on BMS-197525: a potent antagonist of the human thrombin receptor (PAR-1). Bioorg Med Chem Lett 1999, 9:279-284.
19. Escalante Ascota BA, Amezcua , Gastelum JL, Aldana Alcala I: The vascular effects of thrombin on canine and human arteries and their independence from the metabolism of arachadonic acid. Arch Inst Cardiol Mex 1994, 64:433-438.
20. Storck J, Zimmermann ER: Regulation of the thrombin receptor response in human endothelial cells. Thromb Res 1996, 81:121-131.
21. Hamilton JR, Nguyen PB, Cocks TM: Atypical Protease-activated receptor mediates endothelium-dependent relaxation of human coronary arteries. Circ Res 1998, 82:1306-1311.
22. Soifer S, Peters K, O'Keefe J, Coughlin S: Disparate temporal expression of the prothrombin and thrombin receptor genes during mouse development. Am J Pathol 1994, 144:60-69.
23. Bernatowicz MS, Klimas CE, Hartl KS, Peluso Mallagretto NJ, Seiler SM: Development of Potent Thrombin Receptor Antagonist Peptides. J Med Chem 1996, 39:4879-87.
24. O'Sullivan CJ, O'Loughlin AJ, Friel AM, Elliot JT, Morrison JJ: PAR function in human pregnant myometrium: effects of thrombin and specific PAR-1 agonist and antagonist [abstract. J Soc Gynecol Invest 2003, 10:299A.